An in vitro and in vivo study on the synergistic effect and mechanism of itraconazole or voriconazole alone and in combination with tetrandrine against Aspergillus fumigatus

Li, Shuixiu; Song, Yanjun; Zhang, Lingling; Shi, Jian-ping; Ma, Zheng-lai; Guo, Hui; Dong, Huiyu; Li, Yiming

doi:10.1099/jmm.0.000120

Cited by 10 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditionally used as immunomodulators and vasodilators, these have produced antifungal synergy with a variety of azoles. Tetrandrine combined with posaconazole has been proposed as an effective solution for persistent and temporary candidiasis [154][155][156][157][158][159]280]. Eucalyptal D and dodecenoic acid are essential oil extracts that have been shown to directly antagonise ABC transporters [160,161].…”

Section: Active Efflux Modulatorsmentioning

confidence: 99%

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox

Kane

Carter

2022

Pharmaceuticals

View full text Add to dashboard Cite

Fungal infections impact the lives of at least 12 million people every year, killing over 1.5 million. Wide-spread use of fungicides and prophylactic antifungal therapy have driven resistance in many serious fungal pathogens, and there is an urgent need to expand the current antifungal arsenal. Recent research has focused on improving azoles, our most successful class of antifungals, by looking for synergistic interactions with secondary compounds. Synergists can co-operate with azoles by targeting steps in related pathways, or they may act on mechanisms related to resistance such as active efflux or on totally disparate pathways or processes. A variety of sources of potential synergists have been explored, including pre-existing antimicrobials, pharmaceuticals approved for other uses, bioactive natural compounds and phytochemicals, and novel synthetic compounds. Synergy can successfully widen the antifungal spectrum, decrease inhibitory dosages, reduce toxicity, and prevent the development of resistance. This review highlights the diversity of mechanisms that have been exploited for the purposes of azole synergy and demonstrates that synergy remains a promising approach for meeting the urgent need for novel antifungal strategies.

show abstract

Section: Active Efflux Modulatorsmentioning

confidence: 99%

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox

Kane

Carter

2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Traditionally used as immunomodulators and vasodilators, these have produced antifungal synergy with a variety of azoles. Tetrandrine combined with posaconazole has been proposed as an effective solution for persistent and temporary candidiasis [149][150][151][152][153][154]278]. Eucalyptal D and dodecenoic acid are essential oil extracts that have been shown to directly antagonise ABC transporters [155,156].…”

Section: Active Efflux Modulatorsmentioning

confidence: 99%

Augmenting Azoles with Drug Synergy to Expand The Antifungal Toolbox

Kane¹,

Carter²

2022

Preprint

View full text Add to dashboard Cite

Fungal infections impact the lives of at least 12 million people every year, killing over 1.5 million. Wide-spread use of fungicides and prophylactic antifungal therapy have driven resistance in many serious fungal pathogens, and there is an urgent need to expand the current antifungal ar-senal. Recent research has focused on improving azoles, our most successful class of antifungals, by looking for synergistic interactions with secondary compounds. Synergists can co-operate with azoles by targeting steps in related pathways, or they may act on mechanisms related to re-sistance like active efflux or on totally disparate pathways or processes. A variety of sources of potential synergists have been explored, including pre-existing antimicrobials, pharmaceuticals approved for other uses, bioactive natural compounds and phytochemicals, and novel synthetic compounds. Synergy can successfully widen the antifungal spectrum, decrease inhibitory dosag-es, reduce toxicity, and prevent the development of resistance. This review highlights the diversity of mechanisms that have been exploited for the purposes of azole synergy and demonstrates that synergy remains a promising approach for meeting the urgent need for novel antifungal strate-gies.

show abstract

“…Polymeric micelles present a unique architecture where the hydrophobic core can incorporate hydrophobic drugs, such as antifungals, which leads to a very significant improvement in their aqueous solubility [134]. These systems have attracted attention in drug delivery because their critical micelle concentration (CMC) is several 1000-fold lower (<10 mg/L) than classic micelles, this means that ionic surfactants have greater ease in self-assembling in water to form micelles [157].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing

2022

View full text Add to dashboard Cite

show abstract

An in vitro and in vivo study on the synergistic effect and mechanism of itraconazole or voriconazole alone and in combination with tetrandrine against Aspergillus fumigatus

Cited by 10 publications

References 36 publications

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox

Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox

Augmenting Azoles with Drug Synergy to Expand The Antifungal Toolbox

Advances in Antifungal Development: Discovery of New Drugs and Drug Repurposing

Contact Info

Product

Resources

About